BridgeBio Pharma (BBIO) Treasury Shares (2017 - 2026)

BridgeBio Pharma has disclosed Treasury Shares across 7 years of filings, most recently posting $405.8 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $405.8 million, up 25.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $405.8 million (up 25.52% YoY), and the FY2025 annual result was $323.3 million, up 17.55% from the prior year.
• Treasury Shares came in at $405.8 million for Q1 2026 at BridgeBio Pharma, up from $323.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $12.8 million in Q1 2025 to a low of $194943.0 in Q2 2025.
• The 5-year median for Treasury Shares is $6.2 million (2022), against an average of $6.4 million.
• Peak annual rise in Treasury Shares reached 120.0% in 2022, while the deepest fall reached 0.0% in 2022.
• BridgeBio Pharma's Treasury Shares stood at $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then advanced by 17.55% to $323.3 million in 2025, then grew by 25.52% to $405.8 million in 2026.
• The last three Treasury Shares figures came in at $405.8 million (Q1 2026), $323.3 million (Q4 2025), and $323.3 million (Q3 2025), per Business Quant data.